Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa Study of MT-1303 in Moderate to Severe Chronic Plaque Psoriasis
2012-005750-27Phase 2Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in plaque psoriasis and psoriasis comparing MT-1303 with Placebo (2 arms). Primary endpoint: PASI 75 response at Week 16. Started Jun 2013; status: completed.
02
Drugs
amiselimod
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on 2012-005750-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005750-27.